521 related articles for article (PubMed ID: 11890515)
1. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
2. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
Ballard SA; Gingell CJ; Tang K; Turner LA; Price ME; Naylor AM
J Urol; 1998 Jun; 159(6):2164-71. PubMed ID: 9598563
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Wallis RM; Corbin JD; Francis SH; Ellis P
Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor.
Kim NN; Huang YH; Goldstein I; Bischoff E; Traish AM
Life Sci; 2001 Sep; 69(19):2249-56. PubMed ID: 11669467
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
6. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
7. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.
Doh H; Shin CY; Son M; Ko JI; Yoo M; Kim SH; Kim WB
Arch Pharm Res; 2002 Dec; 25(6):873-8. PubMed ID: 12510841
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Firoozi F; Longhurst PA; White MD
BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
12. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
Filippi S; Morelli A; Sandner P; Fibbi B; Mancina R; Marini M; Gacci M; Vignozzi L; Vannelli GB; Carini M; Forti G; Maggi M
Endocrinology; 2007 Mar; 148(3):1019-29. PubMed ID: 17138653
[TBL] [Abstract][Full Text] [Related]
13. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit.
Thompson CS; Mumtaz FH; Khan MA; Wallis RM; Mikhailidis DP; Morgan RJ; Angelini GD; Jeremy JY
Eur J Pharmacol; 2001 Aug; 425(1):57-64. PubMed ID: 11672575
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.
Moreland RB; Goldstein I; Traish A
Life Sci; 1998; 62(20):PL 309-18. PubMed ID: 9600334
[TBL] [Abstract][Full Text] [Related]
15. Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.
Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Takagi M; Kikkawa K; Omori K
J Med Chem; 2001 Jun; 44(13):2204-18. PubMed ID: 11405657
[TBL] [Abstract][Full Text] [Related]
16. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
17. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection.
Bischoff E; Schneider K
Int J Impot Res; 2001 Aug; 13(4):230-5. PubMed ID: 11494080
[TBL] [Abstract][Full Text] [Related]
18. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
19. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of vardenafil (a PDE-5 Inhibitor) on corpus cavernosal smooth muscle relaxation in diabetic rabbits.
Lau DH; Mumtaz FH; Mikhailidis DP; Thompson CS
Urol Int; 2009; 82(1):101-7. PubMed ID: 19172107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
